Wound Management Technologies to market CellerateRx within the U.S.

Dec 4 2009

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a rapidly growing provider of specialty medical products, announced today an agreement with the Health Industry Representative Association (HIRA) to serve as a non-exclusive independent sales and marketing representative to market the company's core CellerateRx® product within the U.S.

HIRA will market and sell Wound Management Technologies' CellerateRx® throughout the U.S. CellerateRx®, is used in the management of pressure ulcers, traumatic wounds, diabetic ulcers, first and second degree burns, venous stasis ulcers, ulcers due to arterial insufficiency and superficial wounds. CellerateRx® targets a worldwide market in excess of several billion dollars.

"HIRA brings an additional avenue for serious market penetration to our sales organization," said Cathy Bradshaw, President of Wound Care Innovations, the division that markets CellerateRx®. "We continue to work to increase the size of our sales force and market share. The third quarter 2009 numbers show that our efforts are paying off; our next benchmark is to become profitable in 2010 and bring earnings to the bottom line as quickly as possible," stated WNDM CEO Scott Haire.